BridgeBio Pharma, Inc.
BBIO
$76.08
$1.321.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 7.21% | 14.94% | -5.54% | -0.46% | -8.65% |
| Total Depreciation and Amortization | -11.21% | -17.35% | 2.65% | 6.15% | 2.57% |
| Total Amortization of Deferred Charges | 5.88% | 25.28% | -67.84% | 214.63% | -11.47% |
| Total Other Non-Cash Items | -1.21% | 5.43% | 17.92% | -9.94% | -2.95% |
| Change in Net Operating Assets | 92.55% | -351.44% | 1,362.05% | -120.24% | 116.72% |
| Cash from Operations | 63.96% | -249.66% | 48.51% | -35.81% | 59.50% |
| Capital Expenditure | -542.03% | -109.09% | 92.98% | 20.88% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 142.96% | -197.93% | -390.25% | 139.76% | -677.93% |
| Cash from Investing | 141.85% | -197.72% | -421.55% | 134.33% | -715.17% |
| Total Debt Issued | -100.00% | -- | -- | -100.00% | -47.83% |
| Total Debt Repaid | -- | -- | -- | 100.00% | 99.56% |
| Issuance of Common Stock | -81.38% | 112.34% | 64.74% | 12.03% | 24.33% |
| Repurchase of Common Stock | -52.21% | -1,065.20% | -145.62% | -51.63% | 96.01% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 145.09% | -202.47% | -35.24% | -426.74% | 90.17% |
| Cash from Financing | -127.05% | 25,301.28% | -144.07% | -100.30% | 400.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -165.18% | 524.75% | 31.18% | -150.88% | 248.30% |